Niacin-and-statin trial ends early; no benefit to raising HDL

The <a class="taxInlineTagLink" id="ORGOV0000101" title="National Institutes of Health" href="/topic/health/health-organizations/national-institutes-of-health-ORGOV0000101.topic">NIH</a> announced May 26 it has stopped a trial 18 months ahead of schedule after finding that combining extended-release, high-dose niacin with a statin doesn't seem to reduce the risk of adverse cardiovascular events like <a class="taxInlineTagLink" id="HEISY000062" title="Heart Attack (INACTIVE)" href="/topic/health/heart-attack-%28inactive%29-HEISY000062.topic">heart attacks</a> and strokes.

( iStock photo )

The NIH announced May 26 it has stopped a trial 18 months ahead of schedule after finding that combining extended-release, high-dose niacin with a statin doesn't seem to reduce the risk of adverse cardiovascular events like heart attacks and strokes.

  • Email E-mail
  • add to Twitter Twitter
  • add to Facebook Facebook
Advertisement